MGRX — MANGOCEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1938046 ·
Last close
$0.38
Market Cap
$8.26M
52W High
$1.25
52W Low
$0.26
ADV30
26,769,113
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 67,864 | 29,001 | -3,126,326 | -3,403,150 | 14,449,223 | 174,562 | 974,571 |
| Dec 2025 | 94,360 | 47,475 | -1,490,378 | -2,769,567 | 16,089,573 | 1,486,338 | 890,568 |
| Sep 2025 | 84,246 | 50,899 | -7,542,926 | -7,618,218 | 16,531,802 | 481,281 | 804,275 |
| Jun 2025 | 168,109 | 89,948 | -5,268,495 | -5,415,818 | 20,842,828 | 101,019 | 1,600,945 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,886,817
Investing CF
$0
Financing CF
$4,985,855
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.60
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-44,050,630
Inventory
$0
Receivables
$20,056
ST Investments
—
EBIT TTM
$-18,813,079
Pretax Income TTM
$-19,207,107
Interest Exp TTM
$394,028
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$315,227
EBITDA
$-12,373,888
Free Cash Flow
$1,351,690
Enterprise Value
$8,310,978
Total Cash
$228,688
Total Debt
$279,207
Shares Out
21,567,422
Trailing EPS
$-1.00
Book Value
$0.69
ROE
-95.1%
ROA
-48.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 456,021 | -19,154,988 | -20,642,994 | 16,089,573 | 890,568 | — | -5,850,255 |
| Dec 2024 | 615,873 | -8,693,526 | -8,706,145 | 15,370,511 | 1,425,463 | — | -4,863,776 |
| Dec 2023 | 731,493 | -9,218,890 | -9,212,417 | 1,050,793 | 276,039 | — | -6,997,375 |
| Dec 2022 | 8,939 | -1,991,582 | -1,998,055 | 1,003,287 | 389,257 | — | -1,346,518 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HLYK | HealthLynked Corp | $8.12M | $2.75 | — |
| ACON | Aclarion, Inc. | $7.67M | $2.66 | — |
| BMGL | Basel Medical Group Ltd | $7.51M | $4.80 | — |
| AMS | AMERICAN SHARED HOSPITAL SERVICES | $9.51M | $1.43 | — |
| BICX | BioCorRx Inc. | $6.64M | $0.22 | — |
News headlines (Yahoo Finance, 1h cache)
Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets
2026-08-13 20:05 · Yahoo
Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor
2026-07-30 14:35 · Yahoo
Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development
2026-08-05 20:05 · Yahoo
Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination
2026-08-04 20:05 · Yahoo
Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology
2026-07-30 11:00 · Yahoo
Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
2026-03-17 20:00 · Yahoo
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
2026-03-06 21:00 · Yahoo
Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
2026-02-23 21:05 · Yahoo
MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program
2026-02-19 21:05 · Yahoo
Top Midday Decliners
2025-12-19 18:46 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.